FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the ...

The authors of this review assess the role of endoscopic retrograde cholangiopancreatography (ERCP) and emerging endoscopic techniques in the diagnosis, treatment, and management of primary sclerosing ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

Effective treatments for patients with primary biliary cholangitis are limited. Seladelpar, a peroxisome proliferator–activated receptor delta agonist, has potential benefits. In this phase 3, ...

Sclerosing cholangitis and primary biliary cirrhosis, which is now called primary biliary cholangitis (PBC), are chronic cholestatic liver diseases, but they differ in their causes, affected bile ...

—According to the results of a new international study, there may be a role for insulin-like growth factor-binding protein 4 (IGFBP4) in facilitating the interaction between macrophages and injured ...

Intercept Pharmaceuticals has voluntarily withdrawn Ocaliva (obeticholic acid) for the treatment of primary biliary cholangitis (PBC) from the US market. The decision follows a request from the FDA.

Cholangitis describes inflammation in the bile ducts or biliary system. Some forms of cholangitis can be life threatening. The condition may cause symptoms such as fever, sweating, abdominal pain, and ...

A major retrospective study shows that people with blood group A face a higher likelihood of autoimmune liver disease, especially primary biliary cholangitis, while those with blood group B appear ...

Primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) both damage bile ducts and can cause bile buildup, inflammation, and scarring in the liver. PBC mainly affects small bile ...